EVOQ Therapeutics

Executive Summary

EVOQ Therapeutics is a preclinical-stage biotechnology company pioneering NanoDisc-based immunotherapies to restore immune tolerance in autoimmune diseases. Its platform leverages synthetic nanodiscs to deliver disease-relevant antigens and regulatory signals, aiming to re-educate the immune system without broad immunosuppression. The pipeline targets Type 1 Diabetes (T1D), Celiac Disease, and Lupus, each representing significant unmet medical needs with large patient populations. Preclinical data have demonstrated proof-of-concept in animal models, showing induction of antigen-specific regulatory T cells and reversal of disease symptoms. With a strong intellectual property portfolio and seasoned management team, EVOQ is positioned to advance toward clinical trials. The company's approach could offer a paradigm shift in autoimmune treatment, potentially providing durable remission with fewer side effects than current standards of care.

Upcoming Catalysts (preview)

• Q2 2026IND filing for lead program in Type 1 Diabetes50% success
• Q3 2026Presentation of preclinical T1D data at major scientific conference70% success
• Q4 2026Series B financing or strategic partnership60% success